Altrartis Therapeutics Inc. has announced the successful completion of a private offering, raising approximately $11 million. This development is significant as it underscores the company's growth potential and ability to attract substantial investment in a competitive biotech landscape.
The filing, dated October 22, 2026, reveals that the offering was conducted under Rule 506(b) of the Securities Act, which provides a safe harbor for private offerings. Altrartis reported that the total offering amount was $10,999,977, all of which has been sold, indicating strong interest from investors.
Background
Altrartis Therapeutics Inc. is a corporation incorporated in Delaware in 2025. The company operates out of New York, and while specific SIC descriptions are not provided, it is categorized under the broader biotech industry. The firm has no publicly traded tickers or exchanges listed, indicating its current status as a private entity.
What the Filing Says
The SEC filing notes that the offering was completed with a total of 11 accredited investors. It states, "The total amount sold is $10,999,977, with no remaining balance." This reflects the company's successful engagement with investors and the confidence they have in Altrartis's business model and future prospects.
Impact
The successful fundraising effort may positively impact Altrartis Therapeutics' operations and strategic initiatives. The funds raised are expected to support ongoing projects and potentially facilitate future growth opportunities. The filing did not specify the exact use of proceeds, but such capital is typically allocated towards research and development, operational expenses, or expansion efforts.
What's Next
The filing does not say what happens next. However, the completion of this offering positions Altrartis Therapeutics to leverage the new capital for its future endeavors.